BridgeBio Pharma BBIO 深 沪
等待开盘 10-06 09:30:00 美东时间
66.14
-1.110
-1.65%
华盛通- 最 高68.08
- 今 开67.40
- 成交量 216.86万股
- 最 低 65.46
- 昨 收 67.25
- 总市值 129.30亿
- 52周最高 93.415
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 52.75
- 委 比 90.76%
- 总股本 1.95亿
- 历史最高 93.415
- 量 比 0.70
- 振 幅 3.90%
- 历史最低 4.98
- 每 手 1
- 风险率 7.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BridgeBio(BBIO.US)心脏病疗法acoramidis真实世界研究表现优于辉瑞(PFE.US)竞品药物
BridgeBio Pharma周三宣布，其心脏病疗法acoramidis(美国品牌名为Attruby)在一项真实世界研究中表现优于辉瑞的竞品药物tafamidis(美国品牌名为Vyndamax)。
09-24 08:32
BridgeBio Pharma shares are trading lower. The company reported data showing acoramidis reduced the risk of early clinical worsening versus tafamidis in ATTR-CM.
BridgeBio Pharma shares are trading lower. The company reported data showing acoramidis reduced the risk of early clinical worsening versus tafamidis in ATTR-CM.
09-23 23:07
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
A study comparing acoramidis and tafamidis in ATTR-CM patients using U.S. claims data found acoramidis associated with a 34% reduction in clinical worsening events, including diuretic intensification, heart failure hospitalization, and mortality, and a 43% reduction in diuretic intensification risk. Benefits emerged early and persisted, suggesting improved clinical stability. Additional real-world studies are planned for 2026. Acoramidis is appro...
09-23 11:47
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma announced on September 18, 2026, that its compensation committee approved equity grants of 63,009 restricted stock units (RSUs) to 36 new employees. One-fourth of the shares will vest on November 16, 2027, with the remaining shares vesting quarterly thereafter, contingent on continued employment. The grants were made under Nasdaq Listing Rule 5635(c)(4) and the terms of the Company’s Plan, which was amended in 2023. BridgeBio foc...
09-18 20:01
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain
BridgeBio Pharma Inc. (NASDAQ:BBIO)on Wednesday shared fresh clinical updates on infigratinib. The company’s 52-week treatment with oral infigratinib in the PROPEL 3 study showed favorable trends versus placebo across exploratory endpoints that go beyond growth, including sleep apnea and otitis medi...
09-09 22:33
Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
09-09 20:21
Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRASG12C inhibitor-naïve NSCLC with ORR of 63% (26/41), disease control rate (D...
09-09 04:08
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
BridgeBio Oncology Therapeutics announced new clinical data for its KRAS<sup>G12C</sup> inhibitor BBO-8520, showing a 75% objective response rate (ORR) when combined with pembrolizumab in second-line NSCLC patients previously treated with KRAS<sup>G12C</sup> inhibitors. BBO-8520 monotherapy achieved a 63% ORR and 100% disease control rate in untreated NSCLC patients. The company is prioritizing BBO-8520 in combination with checkpoint inhibitors a...
09-08 20:05
美股大行评级 | 最高735美元！戴尔科技绩后获11家大行上调目标价；MongoDB绩后分歧大，9家上调；4家下调；派拓网络、GitLab、美敦力获多家大行上调目标价
今日重点评级关注：Tigress Financial：维持Liftoff Mobile"买入"评级，目标价从39美元升至41美元；奥本海默：维持SpaceX"跑赢大市"评级，目标价从250美元升至280美元
09-03 13:50
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
